Medpace (MEDP) Rating Lowered to Hold at ValuEngine
Medpace (NASDAQ:MEDP) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
A number of other equities analysts have also recently commented on MEDP. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Thursday, November 1st. BidaskClub cut shares of Medpace from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 31st. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Finally, SunTrust Banks raised shares of Medpace from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research report on Wednesday, October 31st. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Medpace has a consensus rating of “Buy” and an average target price of $44.43.
NASDAQ:MEDP opened at $57.71 on Thursday. Medpace has a 1-year low of $31.75 and a 1-year high of $65.09. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.66 and a quick ratio of 0.66. The firm has a market capitalization of $2.12 billion, a P/E ratio of 26.29, a PEG ratio of 1.48 and a beta of 1.49.
In other Medpace news, major shareholder Medpace Investors, Llc sold 61,141 shares of Medpace stock in a transaction on Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total transaction of $3,680,688.20. Following the completion of the transaction, the insider now directly owns 9,084,369 shares of the company’s stock, valued at $546,879,013.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 114,983 shares of Medpace stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $59.31, for a total transaction of $6,819,641.73. Following the transaction, the chief executive officer now directly owns 351,851 shares of the company’s stock, valued at $20,868,282.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 396,559 shares of company stock valued at $23,422,389. Company insiders own 29.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Sei Investments Co. lifted its holdings in shares of Medpace by 5,087.5% during the second quarter. Sei Investments Co. now owns 4,565 shares of the company’s stock worth $196,000 after buying an additional 4,477 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Medpace during the second quarter worth $400,000. Laurion Capital Management LP acquired a new stake in shares of Medpace during the second quarter worth $29,230,000. PNC Financial Services Group Inc. lifted its holdings in shares of Medpace by 592.9% during the second quarter. PNC Financial Services Group Inc. now owns 54,798 shares of the company’s stock worth $2,356,000 after buying an additional 46,890 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Medpace by 24.9% during the second quarter. Russell Investments Group Ltd. now owns 171,323 shares of the company’s stock worth $7,380,000 after buying an additional 34,121 shares in the last quarter. 67.54% of the stock is owned by institutional investors.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: Is it better to buy a fund with a higher or lower NAV?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.